Altuvoct

Altuvoct is a pharmaceutical product containing Efanesoctocog Alfa, designed for intravenous use. It is used to manage certain medical conditions related to blood clotting. This medication is manufactured by Swedish Orphan Biovitrum Ab (Publ) and is available in the EU market.

Altuvoct, containing the active ingredient Efanesoctocog Alfa, is primarily used for the treatment of hemophilia B. This condition is characterized by a deficiency in clotting factor IX, leading to prolonged bleeding episodes. The medication works by replacing the missing clotting factor, helping to control and prevent bleeding episodes. What is Altuvoct used for? It is typically administered intravenously to manage bleeding episodes and to prevent them from occurring in individuals with hemophilia B.

Common effects of Altuvoct may include localized reactions at the injection site, such as redness, swelling, or pain. Some individuals might experience mild to moderate headaches or nausea. These effects are generally temporary and subside as the body adjusts to the medication. It is important to monitor for any severe or persistent side effects and consult a healthcare provider if necessary.

Altuvoct should be handled with care, ensuring proper storage and administration as directed. It is crucial to inform healthcare providers about any allergies or pre-existing conditions before starting treatment. Patients should also be aware of the potential for allergic reactions and seek immediate medical attention if symptoms such as difficulty breathing or swelling of the face occur.

Altuvoct may interact with other medications, particularly those that affect blood clotting. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol consumption should be moderated, as it can affect the body's ability to clot blood. Additionally, certain foods or supplements that affect blood clotting should be consumed with caution.